In 2023, the Ministry of Health (FDA) approved the drug pegcetacoplan for the treatment of paroxysmal nocturnal hemoglobinuria.
Empaveli (or Syfovre) is an immunosuppressant that prevents complement-dependent destruction of red blood cells. Pegcetacoplane attaches to the complement protein C3, which is part of the body’s defense system (complement system). By blocking the protein, the drug prevents the complement system from attacking red blood cells and is able to control the symptoms of the disease.
Active ingredient: Pegcetacoplan
Prescription medicine
Storage temperature 2-8 degrees
